Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Iparomlimab/Tuvonralimab in Mesothelioma, Malignant: NCT07131345 Clinical Landscape Report 2026
16 September 2026
NCT07131345 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Emicizumab in Hemophilia A: NCT07158606 Clinical Landscape Report 2026
16 September 2026
NCT07158606 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Beta-Thalassemia: NCT07177300 Clinical Landscape Report 2026
16 September 2026
NCT07177300 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SKP-0141 in Hemophilia A: CTRI/2025/09/094511 Clinical Landscape Report 2026
16 September 2026
CTRI/2025/09/094511 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
WVE-N531 in Muscular Dystrophy, Duchenne: NCT07209332 Clinical Landscape Report 2026
16 September 2026
NCT07209332 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Empagliflozin in Kidney Diseases: NCT07175051 Clinical Landscape Report 2026
16 September 2026
NCT07175051 clinical landscape for Kidney Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SPOT-03 in Muscular Dystrophy, Duchenne: NCT07188012 Clinical Landscape Report 2026
16 September 2026
NCT07188012 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bevacizumab in Hemarthrosis: NCT07187661 Clinical Landscape Report 2026
16 September 2026
NCT07187661 clinical landscape for Hemarthrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zilucoplan in Myasthenia Gravis: NCT07215949 Clinical Landscape Report 2026
16 September 2026
NCT07215949 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cizutamig in Myasthenia Gravis: NCT07215650 Clinical Landscape Report 2026
16 September 2026
NCT07215650 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nipocalimab-aahu in Myasthenia Gravis: NCT07217587 Clinical Landscape Report 2026
16 September 2026
NCT07217587 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Inno8 in Hemophilia A: NCT07220564 Clinical Landscape Report 2026
16 September 2026
NCT07220564 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.